Literature DB >> 7705213

Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia.

L R Wiseman1, D Faulds.   

Abstract

Pilocarpine is a cholinergic agonist which stimulates salivary secretion both in individuals with normal salivary gland function and in those with impaired salivary flow (xerostomia or oral dryness). A rapid increase in salivary flow rate is observed following oral pilocarpine administration and peak levels are maintained for at least 1 to 2 hours. Mean salivary flow rates after administration of pilocarpine are 2- to 10-fold higher than after placebo, and no evidence of tolerance to the pharmacological effects of the drug has been observed during prolonged administration for up to 5 months. The clinical efficacy of oral pilocarpine in relieving symptoms of xerostomia (resulting from radiation therapy to the head and neck region or salivary gland dysfunction), including oral dryness and difficulty in chewing, swallowing and speaking, has been demonstrated in double-blind placebo-controlled clinical trials. In these studies, pilocarpine 5 to 10mg 3 times daily increased salivary flow and improved symptoms of xerostomia in a significantly higher percentage of patients than did placebo (54 versus 25% in one study). Preliminary findings indicate that administration of pilocarpine during radiation therapy may reduce the severity of xerostomia; however, this requires further investigation. The majority of patients receiving oral pilocarpine therapy for xerostomia experience adverse events (most commonly sweating); however, these are generally mild and tolerable in nature. Thus, pilocarpine is an effective agent for the treatment of xerostomia, increasing salivary flow and reducing symptom severity to a significantly greater extent than placebo. Further clinical trials should evaluate the potential beneficial effects of pilocarpine on the incidence of dental caries and oral candidiasis during prolonged therapy, its prophylactic efficacy during radiation therapy and its efficacy relative to that of other salivary stimulants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705213     DOI: 10.2165/00003495-199549010-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  34 in total

1.  Oral complications of cancer therapies. Management of salivary dysfunction.

Authors:  D Greenspan
Journal:  NCI Monogr       Date:  1990

2.  Pilocarpine used to stimulate normal saliva production.

Authors: 
Journal:  J Am Dent Assoc       Date:  1985-08       Impact factor: 3.634

3.  Formulation of a stable pilocarpine hydrochloride solution.

Authors:  I S Gibbs; M M Tuckerman
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

4.  Oral pilocarpine for xerostomia.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1994-08-19       Impact factor: 1.909

5.  Major salivary gland function in patients with radiation-induced xerostomia: flow rates and sialochemistry.

Authors:  I H Valdez; J C Atkinson; J A Ship; P C Fox
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-01       Impact factor: 7.038

6.  Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction.

Authors:  I H Valdez; A Wolff; J C Atkinson; A A Macynski; P C Fox
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

7.  Salivary gland 99mTc-scintigraphy: a grading scale and correlation with major salivary gland flow rates.

Authors:  W G Kohn; J A Ship; J C Atkinson; L L Patton; P C Fox
Journal:  J Oral Pathol Med       Date:  1992-02       Impact factor: 4.253

8.  Primary Sjögren's syndrome: a subjective description of the disease.

Authors:  K Bjerrum; J U Prause
Journal:  Clin Exp Rheumatol       Date:  1990 May-Jun       Impact factor: 4.473

9.  Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome.

Authors:  N L Rhodus; M J Schuh
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1991-11

10.  A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients.

Authors:  F G LeVeque; M Montgomery; D Potter; M B Zimmer; J W Rieke; B W Steiger; S C Gallagher; C C Muscoplat
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more
  25 in total

Review 1.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

Review 2.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment.

Authors:  Alessandro Villa; Andy Wolff; Doron Aframian; Arjan Vissink; Jörgen Ekström; Gordon Proctor; Richard McGowan; Nagamani Narayana; Ardita Aliko; Ying Wai Sia; Revan Kumar Joshi; Siri Beier Jensen; Alexander Ross Kerr; Colin Dawes; Anne Marie Lynge Pedersen
Journal:  Clin Oral Investig       Date:  2015-05-22       Impact factor: 3.573

4.  A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA.

Authors:  Charles L Loprinzi; Ernie P Balcueva; Heshan Liu; Jeff A Sloan; Lisa A Kottschade; Philip J Stella; Mark D Carlson; Dennis F Moore; Robin T Zon; Ralph Levitt; Anthony J Jaslowski
Journal:  J Support Oncol       Date:  2011 May-Jun

5.  Muscarinic acetylcholine receptor-mediated tight junction opening is involved in epiphora in late phase of submandibular gland transplantation.

Authors:  Ning-Yan Yang; Chong Ding; Jing Li; Yan Zhang; Ruo-Lan Xiang; Li-Ling Wu; Guang-Yan Yu; Xin Cong
Journal:  J Mol Histol       Date:  2017-01-11       Impact factor: 2.611

Review 6.  Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.

Authors:  Andrew N Davies; Jo Thompson
Journal:  Cochrane Database Syst Rev       Date:  2015-10-05

7.  Regulation of membrane potential and fluid secretion by Ca2+-activated K+ channels in mouse submandibular glands.

Authors:  Victor G Romanenko; Tetsuji Nakamoto; Alaka Srivastava; Ted Begenisich; James E Melvin
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

Review 8.  Xerostomia and hyposalivation: causes, consequences and treatment in the elderly.

Authors:  T O Närhi; J H Meurman; A Ainamo
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

9.  Central muscarinic receptor subtypes involved in pilocarpine-induced salivation, hypertension and water intake.

Authors:  T L Borella; L A De Luca; D S A Colombari; J V Menani
Journal:  Br J Pharmacol       Date:  2008-09-29       Impact factor: 8.739

10.  Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren's Syndrome.

Authors:  Hiroshi Yasuda; Hiroshi Niki
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.